{"id":"https://openalex.org/W2270149033","doi":"https://doi.org/10.1080/19420862.2015.1136761","title":"Secukinumab, a novel anti\u2013IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity","display_name":"Secukinumab, a novel anti\u2013IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity","alternate_titles":[],"publication_year":2016,"publication_date":"2016-01-28","ids":{"openalex":"https://openalex.org/W2270149033","doi":"https://doi.org/10.1080/19420862.2015.1136761","mag":"2270149033","pmid":"https://pubmed.ncbi.nlm.nih.gov/26817498","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4966846"},"language":"en","primary_location":{"id":"doi:10.1080/19420862.2015.1136761","doi":"https://doi.org/10.1080/19420862.2015.1136761","is_oa":true,"landing_page_url":"https://doi.org/10.1080/19420862.2015.1136761","pdf_url":null,"source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2270149033"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1080/19420862.2015.1136761","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091191201","display_name":"Anette Christine Karle","orcid":"https://orcid.org/0000-0002-0567-9708","observed_orcids":["https://orcid.org/0000-0002-0567-9708"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anette Karle","raw_affiliation_strings":["a Novartis Pharma AG , Basel , Switzerland","Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Novartis Pharma AG , Basel , Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089403454","display_name":"Sebastian Spindeldreher","orcid":"https://orcid.org/0000-0003-4682-9538","observed_orcids":["https://orcid.org/0000-0003-4682-9538"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sebastian Spindeldreher","raw_affiliation_strings":["a Novartis Pharma AG , Basel , Switzerland","Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Novartis Pharma AG , Basel , Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101566813","display_name":"Frank Kolbinger","orcid":"https://orcid.org/0009-0001-2877-5030","observed_orcids":["https://orcid.org/0009-0001-2877-5030"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Frank Kolbinger","raw_affiliation_strings":["a Novartis Pharma AG , Basel , Switzerland","Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Novartis Pharma AG , Basel , Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5101566813"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":{"value":2915,"currency":"GBP","value_usd":3575},"apc_paid":{"value":2915,"currency":"GBP","value_usd":3575},"fwci":4.7785,"has_fulltext":true,"cited_by_count":92,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.96060661,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"8","issue":"3","first_page":"536","last_page":"550"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.8690999746322632,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.8690999746322632,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.04170000180602074,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.026900000870227814,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/secukinumab","display_name":"secukinumab","score":1.0},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.8980000019073486},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.7789999842643738},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9319999814033508},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8270000219345093},{"id":"https://openalex.org/keywords/t-cell-epitopes","display_name":"T cell epitopes","score":0.7459999918937683},{"id":"https://openalex.org/keywords/dendritic-cells","display_name":"dendritic cells","score":0.7919999957084656},{"id":"https://openalex.org/keywords/hla-dr","display_name":"HLA-DR","score":0.7829999923706055},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.8140000104904175},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.8159999847412109},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.8309999704360962}],"concepts":[{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.9092869758605957},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.777031660079956},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.7102653384208679},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5923702716827393},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5778275728225708},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5053277611732483},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.4860394597053528},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.46426132321357727},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3606939911842346},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.26337602734565735},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.0},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003713","descriptor_name":"Dendritic Cells","qualifier_ui":"Q000166","qualifier_name":"cytology","is_major_topic":false},{"descriptor_ui":"D003713","descriptor_name":"Dendritic Cells","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008213","descriptor_name":"Lymphocyte Activation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015496","descriptor_name":"CD4-Positive T-Lymphocytes","qualifier_ui":"Q000166","qualifier_name":"cytology","is_major_topic":false},{"descriptor_ui":"D015496","descriptor_name":"CD4-Positive T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D018984","descriptor_name":"Epitopes, T-Lymphocyte","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D018984","descriptor_name":"Epitopes, T-Lymphocyte","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D020381","descriptor_name":"Interleukin-17","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D020381","descriptor_name":"Interleukin-17","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1080/19420862.2015.1136761","doi":"https://doi.org/10.1080/19420862.2015.1136761","is_oa":true,"landing_page_url":"https://doi.org/10.1080/19420862.2015.1136761","pdf_url":null,"source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4966846","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4966846/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4966846/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"MAbs","raw_type":"Text"},{"id":"pmh:oai:europepmc.org:3953167","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4966846","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:26817498","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26817498","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/19420862.2015.1136761","doi":"https://doi.org/10.1080/19420862.2015.1136761","is_oa":true,"landing_page_url":"https://doi.org/10.1080/19420862.2015.1136761","pdf_url":null,"source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2270149033.pdf","grobid_xml":"https://content.openalex.org/works/W2270149033.grobid-xml"},"referenced_works_count":75,"referenced_works":["https://openalex.org/W103280183","https://openalex.org/W338292988","https://openalex.org/W1606819293","https://openalex.org/W1935617463","https://openalex.org/W1969991375","https://openalex.org/W1973354423","https://openalex.org/W1973555453","https://openalex.org/W1975330719","https://openalex.org/W1976548137","https://openalex.org/W1980372175","https://openalex.org/W1980598049","https://openalex.org/W1980850179","https://openalex.org/W1982079188","https://openalex.org/W1984846010","https://openalex.org/W1985437611","https://openalex.org/W1989757089","https://openalex.org/W1993273784","https://openalex.org/W1994479450","https://openalex.org/W2000251753","https://openalex.org/W2002088100","https://openalex.org/W2003560472","https://openalex.org/W2006984401","https://openalex.org/W2013754528","https://openalex.org/W2018922312","https://openalex.org/W2031552244","https://openalex.org/W2032160423","https://openalex.org/W2038135361","https://openalex.org/W2040041622","https://openalex.org/W2046974419","https://openalex.org/W2048087821","https://openalex.org/W2049872026","https://openalex.org/W2050162659","https://openalex.org/W2051233616","https://openalex.org/W2052067610","https://openalex.org/W2064882706","https://openalex.org/W2065303540","https://openalex.org/W2067197313","https://openalex.org/W2074029876","https://openalex.org/W2078385788","https://openalex.org/W2080237150","https://openalex.org/W2080390872","https://openalex.org/W2080705760","https://openalex.org/W2085127303","https://openalex.org/W2091376804","https://openalex.org/W2092233799","https://openalex.org/W2096620879","https://openalex.org/W2099807201","https://openalex.org/W2103524303","https://openalex.org/W2103750969","https://openalex.org/W2106997293","https://openalex.org/W2109254277","https://openalex.org/W2113771841","https://openalex.org/W2114964760","https://openalex.org/W2125412490","https://openalex.org/W2128850730","https://openalex.org/W2129301243","https://openalex.org/W2133606090","https://openalex.org/W2135407326","https://openalex.org/W2136517791","https://openalex.org/W2137101132","https://openalex.org/W2147810684","https://openalex.org/W2148612170","https://openalex.org/W2152603557","https://openalex.org/W2152712154","https://openalex.org/W2153511580","https://openalex.org/W2155294390","https://openalex.org/W2156866935","https://openalex.org/W2159788225","https://openalex.org/W2168814191","https://openalex.org/W2169055269","https://openalex.org/W2171594570","https://openalex.org/W2182900299","https://openalex.org/W2317900027","https://openalex.org/W3156807887","https://openalex.org/W3159852777"],"related_works":["https://openalex.org/W2785439933","https://openalex.org/W2523913862","https://openalex.org/W2944278567","https://openalex.org/W2512873140","https://openalex.org/W4248741944","https://openalex.org/W2940671601","https://openalex.org/W3000372993","https://openalex.org/W1988054374","https://openalex.org/W2937112267","https://openalex.org/W2807978154"],"abstract_inverted_index":{"Secukinumab":[0],"is":[1],"a":[2,33,37],"human":[3,132],"monoclonal":[4,42],"antibody":[5],"that":[6,54],"selectively":[7],"targets":[8],"interleukin-17A":[9],"and":[10,36,95,123,163,170,177,191,221,239],"has":[11],"been":[12],"demonstrated":[13],"to":[14,23,48,116,198],"be":[15,45],"highly":[16],"efficacious":[17],"in":[18,57,90,114,128,146,226,235],"the":[19,74,125,129,147,151,174],"treatment":[20],"of":[21,50,79,131,187,217],"moderate":[22],"severe":[24],"plaque":[25],"psoriasis,":[26],"starting":[27],"at":[28],"early":[29],"time":[30],"points,":[31],"with":[32,160,201,209],"sustained":[34],"effect":[35],"favorable":[38],"safety":[39],"profile.":[40],"Biotherapeutics--including":[41],"antibodies":[43,52],"(mAbs)--can":[44],"immunogenic,":[46],"leading":[47],"formation":[49],"anti-drug":[51],"(ADAs)":[53],"can":[55],"result":[56],"unwanted":[58],"effects,":[59],"including":[60],"hypersensitivity":[61],"reactions":[62],"or":[63],"compromised":[64],"therapeutic":[65],"efficacy.":[66],"To":[67],"gain":[68],"insight":[69],"into":[70],"possible":[71],"explanations":[72],"for":[73],"clinically":[75],"observed":[76],"low":[77,185,192,203],"immunogenicity":[78,84,212,241],"secukinumab,":[80],"we":[81],"evaluated":[82],"its":[83],"potential":[85,141,188,218],"by":[86,168],"applying":[87],"2":[88],"different":[89],"vitro":[91,115,236],"assays:":[92],"T-cell":[93,142,152,164,178,189,193,219,223,227],"activation":[94,165,179,228],"major":[96],"histocompatibility":[97],"complex-associated":[98],"peptide":[99],"proteomics":[100],"(MAPPs).":[101],"For":[102],"both":[103],"assays,":[104,180,229],"monocyte-derived":[105],"dendritic":[106],"cells":[107,157],"(DCs)":[108],"from":[109],"healthy":[110],"donors":[111],"were":[112,144,158],"exposed":[113],"biotherapeutic":[117],"proteins.":[118],"DCs":[119,162],"naturally":[120],"process":[121],"proteins":[122],"present":[124],"derived":[126],"peptides":[127],"context":[130],"leukocyte":[133],"antigen":[134],"(HLA)-class":[135],"II.":[136],"HLA-DR-associated":[137],"biotherapeutic-derived":[138],"peptides,":[139],"representing":[140],"epitopes,":[143],"identified":[145],"MAPPs":[148,175],"assay.":[149],"In":[150,173,206],"assay,":[153],"autologous":[154],"CD4(+)":[155],"T":[156],"co-cultured":[159],"secukinumab-exposed":[161],"was":[166],"measured":[167],"proliferation":[169],"interleukin-2":[171],"secretion.":[172],"analysis":[176],"secukinumab":[181],"consistently":[182],"showed":[183,214],"relatively":[184],"numbers":[186,216],"epitopes":[190,220],"response":[194,224],"rates,":[195],"respectively,":[196],"comparable":[197],"other":[199],"biotherapeutics":[200,208],"known":[202],"clinical":[204,211,240],"immunogenicity.":[205],"contrast,":[207],"elevated":[210],"rates":[213,225],"increased":[215,222],"indicating":[230],"an":[231],"approximate":[232],"correlation":[233],"between":[234],"assay":[237],"results":[238],"incidence.":[242]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2270149033","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":12},{"year":2019,"cited_by_count":12},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
